Document Detail

Arachidonic acid metabolism in benign and malignant prostatic tissue in vitro: effects of fatty acids and cyclooxygenase inhibitors.
MedLine Citation:
PMID:  7512536     Owner:  NLM     Status:  MEDLINE    
Concentrations of fatty acids (FA) in prostatic tissue of patients with either benign or malignant prostatic disease have previously been shown to be significantly different. In particular, there was a significant reduction in arachidonic acid (AA, C20:4n-6) and docosapentaenoic acid (DPA, C22:5n-6) concentrations in malignant prostatic tissue (PCa) phospholipids (PL). It was suggested that the decreased AA concentration in PCa may be due to its increased metabolism via the cyclooxygenase (CO) and/or lipoxygenase (LO) pathways to produce eicosanoids such as prostaglandins (PGs) and/or leukotrienes (LTs) rather than an impairment in desaturase activity in situ. The eicosanoid production in benign prostatic tissue (BPH) and PCa was determined using [3H]AA. The only eicosanoid produced in significant amounts by either tissue was PGE2 and PCa converted radiolabelled AA to PGE2 at an almost 10-fold higher rate than BPH. PGE2 production from [3H]AA by PCa was investigated in the presence of oleic acid (OA, C18:1n-9), eicosapentaenoic acid (EPA, C20:5n-3), docosahexaenoic acid (DHA, C22:6n-3), dihomo-gamma-linolenic acid (DGLA, C20:3n-6), eicosatetraynoic acid (ETYA) and ketoprofen (KPN) respectively. OA was found to be the most effective inhibitor of PGE2 production by PCa compared with DHA, EPA, ETYA and KPN, while DGLA was the least effective. Diacylglycerol (DAG) formation from labelled AA by PCa was about 4-fold greater than in BPH. Such high levels of DAG may be a means of promoting tumorigenesis through activation of protein kinase C as found with phorbol esters which can be regarded as DAG analogues.
A A Chaudry; K W Wahle; S McClinton; L E Moffat
Related Documents :
20181786 - Dha may prevent age-related dementia.
18155686 - Changing ratios of omega-6 to omega-3 fatty acids can differentially modulate polychlor...
19789416 - Blood eicosapentaenoic acid and docosahexaenoic acid as predictors of all-cause mortali...
1390876 - Changes in fatty acid composition in rat blood and organs after infusion of eicosapenta...
8971956 - Dissociate arachidonic acid release from eicosanoid synthesis in rat peritoneal macroph...
3943616 - Studies on the phospholipid composition of pathogenic cell membranes of mycoplasma hyop...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  International journal of cancer. Journal international du cancer     Volume:  57     ISSN:  0020-7136     ISO Abbreviation:  Int. J. Cancer     Publication Date:  1994 Apr 
Date Detail:
Created Date:  1994-05-18     Completed Date:  1994-05-18     Revised Date:  2007-07-24    
Medline Journal Info:
Nlm Unique ID:  0042124     Medline TA:  Int J Cancer     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  176-80     Citation Subset:  IM    
Department of Urology, Aberdeen Royal Infirmary, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
5,8,11,14-Eicosatetraynoic Acid / pharmacology
Arachidonic Acid / metabolism*
Cyclooxygenase Inhibitors / pharmacology*
Fatty Acids, Unsaturated / pharmacology*
Ketoprofen / pharmacology
Prostate / metabolism*
Prostatic Hyperplasia / metabolism*
Prostatic Neoplasms / metabolism*
Reg. No./Substance:
0/Cyclooxygenase Inhibitors; 0/Fatty Acids, Unsaturated; 1191-85-1/5,8,11,14-Eicosatetraynoic Acid; 22071-15-4/Ketoprofen; 506-32-1/Arachidonic Acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The migration of Langerhans' cells into and out of lymph nodes draining normal, carcinogen and antig...
Next Document:  Characterization of monoclonal antibody PAM4 reactive with a pancreatic cancer mucin.